Smartkarma's AI Co-Pilot, Smartkarma

αSK

Smartkarma's AI Co-Pilot

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Bottom-Up

<ul>
  <li>Shanghai Chicmax is a high-growth domestic player rapidly gaining market share in China's large and expanding cosmetics market, driven by its successful multi-brand strategy and strong R&amp;D focus.</li>
  <li>The company's flagship brand, KANS, has demonstrated exceptional growth, particularly in online channels like Douyin, positioning Chicmax as a formidable competitor to both domestic and international brands.</li>
  <li>While valuation appears moderate relative to peers and the company exhibits strong financial performance, risks include intense competition, reliance on the Chinese consumer market, and the challenge of maintaining brand momentum.</li>
</ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>


  Shanghai Chicmax is a high-growth domestic player rapidly gaining market share in China's large and expanding cosmetics market, driven by its successful multi-brand strategy and strong R&amp;D focus.
  The company's flagship brand, KANS, has demonstrated exceptional growth, particularly in online channels like Douyin, positioning Chicmax as a formidable competitor to both domestic and international brands.
  While valuation appears moderate relative to peers and the company exhibits strong financial performance, risks include intense competition, reliance on the Chinese consumer market, and the challenge of maintaining brand momentum.
This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

Primer: Shanghai Chicmax Cosmetic (2145 HK) - Apr 2026

Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

<ul>
<li>The data in this insight is collated from the "shareholding disclosure" link on the HKEx website.</li>
<li>Often there is a corresponding HKEx announcement on the increase - or decrease - in the shareholding by directors. </li>
<li>However, such disclosures are by no means an absolute. These insights also flag those companies where shares have been pledged, both recently and ongoing.</li>
</ul>


The data in this insight is collated from the "shareholding disclosure" link on the HKEx website.
Often there is a corresponding HKEx announcement on the increase - or decrease - in the shareholding by directors. 
However, such disclosures are by no means an absolute. These insights also flag those companies where shares have been pledged, both recently and ongoing.


HK CEO/Director Dealings (31 Oct 2025): Shanghai Chicmax, AuGroup (Shenzhen), Twintek, Rongzun

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

Equity Capital Markets

Guangdong Marubi Biotechnology / Equity Capital Markets

Guangdong Marubi Biotechnology (603983 CH)

<ul>
<li>Marubi's business has formed a clear "dual-brand-driven" structure. Its business model features "brand operation + omni-channel sales". However, strong growth on revenue side contrasts with the pressure on profit side.</li>
<li>Marubi's profitability/expense control are inferior to Giant Biogene. The maturity/stability of brand matrix are not as good as those of PROYA. Marubi also lacks strong IP premium like Mao Geping.</li>
<li>Compliance risks behind performance data have directly shaken the credibility of growth. Intensified industry competition and high traffic costs further squeezed the profit space. Valuation would be lower than peers</li>
</ul>


Marubi's business has formed a clear "dual-brand-driven" structure. Its business model features "brand operation + omni-channel sales". However, strong growth on revenue side contrasts with the pressure on profit side.
Marubi's profitability/expense control are inferior to Giant Biogene. The maturity/stability of brand matrix are not as good as those of PROYA. Marubi also lacks strong IP premium like Mao Geping.
Compliance risks behind performance data have directly shaken the credibility of growth. Intensified industry competition and high traffic costs further squeezed the profit space. Valuation would be lower than peers


Pre-IPO Guangdong Marubi Biotechnology (A/H Listing) - The Pain Points and the Outlook

Asia Pac ECM and Index Rebal, DZT Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of February 6th.</li>
<li>The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.</li>
<li>We highlight flows for Tencent, Xiaomi, SMIC, Pop Mart Intl, Ke, ICBC, Zijin Gold International, Zijin Mining, Hua Hong Semiconductor, Zhaojin Mining Industry.</li>
</ul>


We analyze the weekly Hong Kong Connect flows with our data engine for holding position as of February 6th.
The top stocks by inflows and outflows were tabulated for all market, HSCEI, mid cap and s/mid cap groups.
We highlight flows for Tencent, Xiaomi, SMIC, Pop Mart Intl, Ke, ICBC, Zijin Gold International, Zijin Mining, Hua Hong Semiconductor, Zhaojin Mining Industry.


HK Connect Flows Weekly (Feb 6th): Tencent, Xiaomi, SMIC, Pop Mart Intl, Ke, ICBC

<ul>
<li>Since listing, PROYA's revenue has maintained double-digit growth rate. But in 2025, PROYA lost its momentum. While core brand PROYA was struggling, the multi-brand matrix failed to turn the tide.</li>
<li>The competition for traffic among major brands is becoming increasingly fierce, and the cost of acquiring customers is rising, which has led to the high and growing expenses of PROYA.</li>
<li>Considering PROYA’s current situation of slowing growth, a certain valuation discount may occur. The reasonable P/E ratio range could be 20-25x, lower than peers such as <a href="https://www.smartkarma.com/entities/mao-geping-cosmetics-co-ltd-41b64ec7-42e1-4d89-9424-b63b5ba53ea4" target="_blank" data-smartkarma-citation="entities:1521:1" rel="noopener">Mao Geping</a>, <a href="https://www.smartkarma.com/entities/shanghai-chicmax-cosmetic-co-ltd" target="_blank" data-smartkarma-citation="entities:35503:1" rel="noopener">Chicmax.</a>
</li>
</ul>


Since listing, PROYA's revenue has maintained double-digit growth rate. But in 2025, PROYA lost its momentum. While core brand PROYA was struggling, the multi-brand matrix failed to turn the tide.
The competition for traffic among major brands is becoming increasingly fierce, and the cost of acquiring customers is rising, which has led to the high and growing expenses of PROYA.
Considering PROYA’s current situation of slowing growth, a certain valuation discount may occur. The reasonable P/E ratio range could be 20-25x, lower than peers such as Mao Geping, Chicmax.



Pre-IPO Proya Cosmetics (A/H Listing)- The Downward Trend in Performance May Be Difficult to Reverse

China

Chicmax is a multi-brand cosmetics company specializing in the research, development, production, and sale of skincare, maternity, and childcare products. The company offers a wide range of cosmetics under brands such as KANS, One Leaf, and Baby Elephant. It was founded in 2002 and is headquartered in Shanghai, China.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Chicmax (2145 HK)

Primer: Shanghai Chicmax Cosmetic (2145 HK) - Apr 2026

Shanghai Chicmax is a high-growth domestic player rapidly gaining market share in China's large and expanding cosmetics market, driven by its...

αSK

HK CEO/Director Dealings (31 Oct 2025): Shanghai Chicmax, AuGroup (Shenzhen), Twintek, Rongzun

The data in this insight is collated from the "shareholding disclosure" link on the HKEx website. These insights also flag those companies where...

David Blennerhassett

Pre-IPO Guangdong Marubi Biotechnology (A/H Listing) - The Pain Points and the Outlook

Marubi's dual-brand-driven structure with brand operation+omni-channel sales face profit pressure due to inferior cost control.Compliance risk...

Xinyao (Criss) Wang

HK Connect Flows Weekly (Feb 6th): Tencent, Xiaomi, SMIC, Pop Mart Intl, Ke, ICBC

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Tencent (700 HK), Xiaomi (1810 HK), SMIC (981 HK), Pop...

Ke Yan, CFA, FRM

Pre-IPO Proya Cosmetics (A/H Listing)- The Downward Trend in Performance May Be Difficult to Reverse

PROYA's growth slowed in 2025 due to revenue slowdown of core brand, intense competition, rising customer acquisition cost, thus leading to...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Primer: Shanghai Chicmax Cosmetic (2145 HK) - Apr 2026

Shanghai Chicmax is a high-growth domestic player rapidly gaining market share in China's large and expanding cosmetics market, driven by its...

αSK

HK CEO/Director Dealings (31 Oct 2025): Shanghai Chicmax, AuGroup (Shenzhen), Twintek, Rongzun

The data in this insight is collated from the "shareholding disclosure" link on the HKEx website. These insights also flag those companies where...

David Blennerhassett

Pre-IPO Guangdong Marubi Biotechnology (A/H Listing) - The Pain Points and the Outlook

​Marubi's dual-brand-driven structure with brand operation+omni-channel sales face profit pressure due to inferior cost control.Compliance risk...

Xinyao (Criss) Wang

HK Connect Flows Weekly (Feb 6th): Tencent, Xiaomi, SMIC, Pop Mart Intl, Ke, ICBC

We analyzed southbound Hong Kong connect flows in the past week and highlighted flows for Tencent (700 HK), Xiaomi (1810 HK), SMIC (981 HK), Pop...

Ke Yan, CFA, FRM

Pre-IPO Proya Cosmetics (A/H Listing)- The Downward Trend in Performance May Be Difficult to Reverse

​PROYA's growth slowed in 2025 due to revenue slowdown of core brand, intense competition, rising customer acquisition cost, thus leading to...

Xinyao (Criss) Wang

Marubi's dual-brand-driven structure with brand operation+omni-channel sales face profit pressure due to inferior cost control.Compliance risk...

PROYA's growth slowed in 2025 due to revenue slowdown of core brand, intense competition, rising customer acquisition cost, thus leading to...